Amalgamated Financial’s Oramed Pharmaceuticals ORMP Stock Holding History

Amalgamated Financial’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$56K	Buy	+6,457	New	+$66.2K	﹤0.01%	2376

Other funds holding ORMP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JSMC

Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return

Amalgamated Financial's ORMP Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Oramed Pharmaceuticals (ORMP) in Q1 2022: 6,457 shares worth $56K. The stake represents ﹤0.01% of the portfolio and ranks #2376 among its holdings.

103 funds tracked by Wall St. Rank hold ORMP as of Q1 2022.

Amalgamated Financial held 6,457 shares of Oramed Pharmaceuticals worth $56K as of Q1 2022.
Oramed Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
Oramed Pharmaceuticals made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2376 holding.
103 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.